Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424

[1]  D. Berman,et al.  Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. , 2006, American heart journal.

[2]  L. Shaw,et al.  Atherosclerotic plaque imaging: contemporary role in preventive cardiology. , 2005, Archives of internal medicine.

[3]  L. Shaw,et al.  Tracking atherosclerosis regression: a clinical tool in preventive cardiology. , 2005, Atherosclerosis.

[4]  C. Cannon,et al.  Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation , 2004, Journal of Thrombosis and Thrombolysis.

[5]  Daniel S. Berman,et al.  Prognostic validation of a 17-segment score derived from a 20-segment score for myocardial perfusion spect interpretation , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[6]  L. Shaw,et al.  Adenosine sestamibi spect post-infarction evaluation (inspire) trial: a randomized, prospective multicenter trial evaluating the role of adenosine tc-99m sestamibi spect for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[7]  Antonio Colombo,et al.  Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. , 2004, European heart journal.

[8]  C. Pizzi,et al.  Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. , 2004, The American journal of cardiology.

[9]  L. Shaw,et al.  Prognostic value of gated myocardial perfusion SPECT , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[10]  S. Bergmann,et al.  Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. , 2004, Journal of the American College of Cardiology.

[11]  W. Fang,et al.  Long-term prognostic value of exercise 99mTc-MIBI SPET myocardial perfusion imaging in patients after percutaneous coronary intervention , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  P. J. Ell,et al.  Myocardial perfusion scintigraphy: the evidence , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  E. Antman,et al.  ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionucl , 2003, Journal of the American College of Cardiology.

[14]  E. Antman,et al.  ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionucl , 2003, Journal of the American College of Cardiology.

[15]  R. Blumenthal,et al.  New insights into the relationship between myocardial perfusion and lipid-lowering. , 2003, Journal of the American College of Cardiology.

[16]  Abrar H. Shah,et al.  Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. , 2003, Journal of the American College of Cardiology.

[17]  M. Pfisterer,et al.  Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. , 2003, Journal of the American College of Cardiology.

[18]  A. Kaltoft,et al.  Electrocardiographic Gated 99mTc-Sestamibi SPECT Immediately after Primary Percutaneous Coronary Intervention Characterizes Reperfusion Success , 2003, Cardiology.

[19]  D. Berman,et al.  Comparison of the Short‐Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery Disease Undergoing Stress Myocardial Perfusion Single Photon Emission Computed Tomography , 2003, Circulation.

[20]  A. Iskandrian,et al.  Role of single photon emission computed tomography imaging in the evaluation of therapy for angina pectoris. , 2003, American heart journal.

[21]  N. Sattar,et al.  Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome , 2003, The Lancet.

[22]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[23]  F. Coppi,et al.  Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. , 2002, Journal of the American College of Cardiology.

[24]  V. Fuster,et al.  AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.

[25]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[26]  R. Schwartz.  Beyond the cholesterol profile: Monitoring therapeutic effectiveness of statin therapy , 2001, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[27]  David O. Williams,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[28]  D. Berman,et al.  Resolution of stress-induced myocardial ischemia during aggressive medical therapy as demonstrated by single photon emission computed tomography imaging. , 2001, Circulation.

[29]  S. Alam,et al.  Resolution of perfusion defects with antiischemic medical therapy , 2000, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[30]  H. Eichstädt,et al.  Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. , 2000, Journal of cardiovascular pharmacology.

[31]  R. Nohara,et al.  Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. , 2000, Japanese circulation journal.

[32]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[33]  L. Shaw,et al.  Prognostic value of thallium-201 single-photon emission computed tomography for patients with multivessel coronary artery disease after revascularization (the Emory Angioplasty versus Surgery Trial [EAST]). , 1999, The American journal of cardiology.

[34]  J. Murray,et al.  ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. , 1999, Journal of the American College of Cardiology.

[35]  S. Port.  Imaging guidelines for nuclear cardiology procedures , 1999 .

[36]  M. Verani,et al.  Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. , 1998, Circulation.

[37]  M. Lauer,et al.  Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting , 1998, The Lancet.

[38]  P. Hartigan,et al.  Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) Study. , 1997, Journal of the American College of Cardiology.

[39]  D. Waters,et al.  Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. , 1997, The American journal of cardiology.

[40]  D. Berman,et al.  Achieving sustained improvement in myocardial perfusion: role of isosorbide mononitrate. , 1997, The American journal of cardiology.

[41]  M. Omata,et al.  Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. , 1996, Circulation.

[42]  E. Milan,et al.  Technetium-99m-sestamibi SPECT to detect restenosis after successful percutaneous coronary angioplasty. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  R. Califf,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. , 1996, Journal of the American College of Cardiology.

[44]  V. Fuster,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. , 1996, Journal of the American College of Cardiology.

[45]  N. Mullani,et al.  Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. , 1995, JAMA.

[46]  A. Zeiher,et al.  Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. , 1995, Circulation.

[47]  K. Gould,et al.  Reversal of coronary atherosclerosis. Clinical promise as the basis for noninvasive management of coronary artery disease. , 1994, Circulation.

[48]  M. Verani,et al.  Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. , 1994, Journal of the American College of Cardiology.

[49]  B. Chaitman,et al.  Correlation of pharmacological 99mTc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. , 1994, Circulation.

[50]  M. Pfisterer,et al.  Silent ischemia after percutaneous transluminal coronary angioplasty: incidence and prognostic significance. , 1993, Journal of the American College of Cardiology.

[51]  A. Takeshita,et al.  Effect of nitroglycerin on coronary collateral function during exercise evaluated by quantitative analysis of thallium-201 single photon emission computed tomography. , 1991, American heart journal.

[52]  H. Hecht,et al.  Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. , 1991, Journal of the American College of Cardiology.

[53]  Thomas R. Bruce,et al.  Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal coronary angioplasty. , 1990, The American journal of cardiology.

[54]  T. Ryan.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[55]  J. Barnes,et al.  Incomplete revascularization in multivessel percutaneous transluminal coronary angioplasty: the role for stress thallium-201 imaging. , 1988, Journal of the American College of Cardiology.

[56]  H. Keller,et al.  Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. , 1988, The American journal of cardiology.

[57]  R. Miller,et al.  Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hypoperfusion in stable angina. , 1982, The American journal of cardiology.

[58]  H. Hirzel,et al.  Short‐ and Long‐term Changes in Myocardial Perfusion After Percutaneous Transluminal Coronary Angioplasty Assessed by Thallium‐201 Exercise Scintigraphy , 1981, Circulation.

[59]  R. Gibbons.  ACC/AHA guideline for management of patients with chronic stable angina , 2003 .

[60]  D. Berman,et al.  When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. , 2001, Journal of the American College of Cardiology.

[61]  L. Martín-Jadraque,et al.  Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. , 2000, Journal of the American College of Cardiology.

[62]  T. Sharir,et al.  Anti-ischemic drugs reduce size of reversible defects in dipyridamole/submaximal exercise TI-201 SPECT imaging , 1997 .

[63]  R. Kloiber,et al.  Sequential thallium-201 myocardial perfusion studies after successful percutaneous transluminal coronary artery angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. , 1988, Circulation.